Latuda Dosing Schedule
Latuda (lurasidone) should be started at 40 mg once daily for adults with schizophrenia and 20 mg once daily for adults with bipolar I depression, taken with at least 350 calories of food, with no initial titration required. 1
Schizophrenia Dosing
Adults
- Starting dose: 40 mg once daily
- Effective range: 40-160 mg/day
- Maximum dose: 160 mg/day
- No initial titration required 1
Adolescents (13-17 years)
- Starting dose: 40 mg once daily
- Effective range: 40-80 mg/day
- Maximum dose: 80 mg/day
- No initial titration required 1
Bipolar I Depression Dosing
Adults (Monotherapy or Adjunctive with Lithium/Valproate)
- Starting dose: 20 mg once daily
- Effective range: 20-120 mg/day
- Maximum dose: 120 mg/day
- No initial titration required
- Important note: The 80-120 mg/day range did not provide additional efficacy compared to 20-60 mg/day in monotherapy studies 1
Pediatric Patients (10-17 years, Monotherapy)
- Starting dose: 20 mg once daily
- Dose adjustment: May increase after one week based on clinical response
- Effective range: 20-80 mg/day
- Maximum dose: 80 mg/day
- Clinical note: 67% of patients in trials received 20-40 mg/day 1
Recent meta-analysis data suggests 40-60 mg/day is optimal for bipolar depression, balancing efficacy with side effect burden 2. Asian expert consensus recommends a starting dose of 20 mg/day with titration up to 120 mg/day as needed 3.
Critical Administration Requirement
Latuda MUST be taken with food (at least 350 calories) to ensure adequate absorption. Food increases:
Without food, bioavailability is substantially reduced, potentially leading to treatment failure.
Dose Adjustments for Hepatic Impairment
Moderate Hepatic Impairment (Child-Pugh Score 7-9)
- Starting dose: 20 mg/day
- Maximum dose: 80 mg/day 1
Severe Hepatic Impairment (Child-Pugh Score 10-15)
- Starting dose: 20 mg/day
- Maximum dose: 40 mg/day 1
Dose Adjustments for Renal Impairment
Moderate Renal Impairment (CrCl 30 to <50 mL/min)
- Starting dose: 20 mg/day
- Maximum dose: 80 mg/day 1
Severe Renal Impairment (CrCl <30 mL/min)
- Starting dose: 20 mg/day
- Maximum dose: 80 mg/day 1
Drug Interactions: CYP3A4 Considerations
Lurasidone is primarily metabolized by CYP3A4, requiring careful attention to drug interactions 4, 5.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir)
Moderate CYP3A4 Inhibitors (e.g., diltiazem, erythromycin, fluconazole)
- Starting dose: 20 mg/day
- Maximum dose: 80 mg/day 1
Strong CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort)
Moderate CYP3A4 Inducers
- May require dose increase; monitor clinical response 1
Genetic Considerations
CYP3A4 rs2242480 genotype influences lurasidone clearance:
- CC carriers: 25% lower clearance compared to TT carriers
- TC carriers: 14% lower clearance compared to TT carriers
- Consider lower doses in CC carriers, particularly when targeting AUC of 167 mg·h·L⁻¹ (optimal efficacy threshold) 6
Special Populations
Elderly Patients
Asian expert consensus recommends a lower dose range of 20-80 mg/day with careful monitoring 3
Pregnancy
Exercise caution, particularly in the first trimester 3
Common Pitfalls to Avoid
- Forgetting food requirement: Always emphasize the 350-calorie minimum with each dose
- Exceeding 80 mg/day in schizophrenia without benefit: Doses above 80 mg/day may increase side effects (somnolence, akathisia) without additional efficacy 4, 7
- Missing CYP3A4 interactions: Always screen for strong inhibitors/inducers before prescribing
- Over-titrating in bipolar depression: The 20-60 mg/day range is often sufficient; higher doses (80-120 mg/day) showed no additional benefit in monotherapy 1
- Inadequate trial duration: Allow at least 4-6 weeks at therapeutic dose before declaring treatment failure 8
Monitoring
- Efficacy assessment: Evaluate response at 4-6 weeks 8
- Side effects: Monitor for akathisia, extrapyramidal symptoms, somnolence, and nausea 9, 7
- Metabolic profile: Lurasidone has minimal impact on weight, glucose, and lipids 4, 5, 7
- Long-term use: Periodically re-evaluate necessity beyond 6 weeks, as long-term efficacy data is limited 1